Abstract
The purpose of this paper is to describe and illustrate an outcome-adaptive Bayesian procedure, proposed by Thall and Cook (2004), for assigning doses of an experimental treatment to successive cohorts of patients. The method uses elicited (efficacy, toxicity) probability pairs to construct a family of trade-off contours that are used to quantify the desirability of each dose. This provides a basis for determining a best dose for each cohort. The method combines the goals of conventional Phase I and Phase II trials, and thus may be called a "Phase I-II" design. We first give a general review of the probability model and dose-finding algorithm. We next describe an application to a trial of a biologic agent for treatment of acute myelogenous leukemia, including a computer simulation study to assess the design's average behavior. To illustrate how the method may work in practice, we present a cohort-by-cohort example of a particular trial. We close with a discussion of some practical issues that may arise during implementation.
Original language | English (US) |
---|---|
Pages (from-to) | 623-638 |
Number of pages | 16 |
Journal | Journal of Biopharmaceutical Statistics |
Volume | 16 |
Issue number | 5 |
DOIs | |
State | Published - Oct 1 2006 |
Keywords
- Acute leukemia
- Adaptive design
- Bayesian design
- Phase I clinical trial
- Phase I-II clinical trial
ASJC Scopus subject areas
- Statistics and Probability
- Pharmacology
- Pharmacology (medical)